Robert E. Funck is President & CFO +1 at ABBOTT LABORATORIES (ABT). They have made 7 open-market trades across 1 company since 2014, most recently 2021-04-28.
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 7 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| ABT | 188,650 | $21.8M |
Shares reported on the most recent Form 4, priced at the 2021-04-30 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| ABT | SELL | 2020-10-26 | 2020-10-28 | $108.83 | $18.1M | +2.8% | +1.2% | +7.8% |
| ABT | SELL | 2020-03-02 | 2020-03-03 | $77.89 | $211K | +1.2% | -1.5% | +15.3% |
| ABT | SELL | 2019-03-01 | 2019-03-04 | $78.00 | $78K | +0.5% | +1.2% | -3.6% |
| ABT | SELL | 2018-03-01 | 2018-03-02 | $58.99 | $144K | +6.7% | -1.2% | +4.4% |
| ABT | SELL | 2017-02-23 | 2017-02-24 | $45.50 | $1.2M | -0.3% | -1.8% | -3.4% |
| ABT | SELL | 2016-07-25 | 2016-07-27 | $43.08 | $1.2M | +2.3% | -2.4% | -8.7% |
| ABT | SELL · 10b5-1 | 2016-02-29 | 2016-03-02 | $39.31 | $52K | +5.0% | +9.4% | +2.8% |
| ABT | SELL · 10b5-1 | 2014-03-03 | 2014-03-04 | $38.97 | $55K | -8.3% | -2.3% | -2.3% |
| ABT | SELL | 2014-01-31 | 2014-02-04 | $36.20 | $340K | -8.3% | -2.3% | -2.3% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.